Steven G. Waguespack

In the first interview of this series, Steven G. Waguespack, MD, considers long-term safety and efficacy data on larotrectinib and discusses implications for the treatment landscape for NTRK fusion-positive thyroid cancer.

In this first video of the series, Steven G. Waguespack, MD, of the University of Texas MD Anderson Cancer Center provides an overview of the safety and efficacy of larotrectinib and considers how it has impacted the treatment landscape for NTRK fusion-positive cancers.